SANGUI BIOTECH INTERNATIONAL INC Form NT 10-Q

November 15, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one):
o Form 10-K
o Form 20-F
o Form 11-K
x Form 10-Q
o Form 10-D
o Form N-SAR
o Form N-CSR
For Period Ended: September 30, 2012
o Transition Report on Form 10-K
o Transition Report on Form 20-F
o Transition Report on Form 11-K

o Transition Report on Form 10-Q
o Transition Report on Form N-SAR
For the Transition Period Ended:
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification related to a portion of the filing checked above, identify the Item(s) to which the notification relates
PART I
REGISTRANT INFORMATION
Sangui Biotech International, Inc.
Full Name of Registrant
Not Applicable
Former Name if Applicable
Alfred-Herrhausen-Str. 44, 58455, Witten, Germany
Address of Principal Executive Office

PART II

RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate).

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth
- calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 - (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III

NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report or portion thereof, could not be filed within the prescribed period.

The Company was met with delays in the xbrl process. The process of tagging the relevant information required in the Form 10-Q for the relevant fiscal period, as well as the completion of the required review of said information, could not be completed without incurring undue hardship and expense due to the fact that the subsidiary of the Company is a GmbH in Germany and all accounting matters must be translated and then made United States GAAP compliant prior to xbrl tagging. The Company undertakes the responsibility to file such annual report no later than five days after its original date.

PART IV

OTHER INFORMATION

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Sangui Biotech International, Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November /s/ Thomas Striepe

15, 2012

By: Thomas Striepe

President and Chief Executive Officer